Skip to content

Effects of Esmolol on the Median Effective Dose of Esketamine in Children Undergoing Ambulatory Surgery

Effects of Esmolol on the Median Effective Dose of Esketamine in Children Undergoing Ambulatory Surgery

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061480
Enrollment
Unknown
Registered
2022-06-26
Start date
2022-06-13
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension and tachycardia caused by esketamine

Interventions

Control group:None
Intervention group:Esmolol 0.5 mg/kg administrated intravenously for 30 seconds after a dose of esketamine

Sponsors

Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
3 Years to 7 Years

Inclusion criteria

Inclusion criteria: 1. Healthy children aged 3–7 years who underwent circumcision. 2. Written informed consent was obtained from the parents or legal guardians of the children.

Exclusion criteria

Exclusion criteria: 1. Allergic to Esketamine. 2. Dysfunction of liver and kidney. 3. History of asthma. 4. ASA grade >=2. 5. Other systemic diseases.

Design outcomes

Primary

MeasureTime frame
Body movement;

Secondary

MeasureTime frame
Vital signs (Noninvasive blood pressure, heart rate, pulse oxygen saturation);

Countries

China

Contacts

Public ContactLi Bo

Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine

libo@scmc.com.cn+86 13818402827

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026